BioVie Reports Distinct Biomarker Responses In Phase 2 Long COVID Trial; Stock Down

BioVie Inc. (BIVI) reported distinct biomarker responses in its Phase 2 ADDRESS-LC trial for Long COVID treatment. Two patient groups showed different responses to bezisterim, with high-inflammatory patients improving in cognitive function and low-WBC patients in fatigue and PEM. The stock is down 0.75% to $1.32.

Original reporting
Published Nov 9, 2026, 5:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 5:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BIVI
Neutral
high confidence
Mentioned
$BIVI
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$BIVINeutralMed
01

Why it matters

The new biomarker‑defined subgroup data provide early signals of efficacy but also highlight variability, influencing valuation and pipeline expectations.

02

Market read

First public disclosure of Phase 2 subgroup results; modest price move suggests limited immediate impact but informs longer‑term valuation.

03

What to watch

Potential for the drug to advance in other neurodegenerative indications such as Parkinson's or Alzheimer's.

Relevance 8/10Novelty 8/10Timing: today

Background

BioVie is a clinical‑stage biotech focused on neuro‑inflammatory diseases; its Long COVID trial is part of a broader pipeline.

Company-level read

Ticker impact

$BIVINeutralHigh confidence
Context

BioVie disclosed new Phase 2 biomarker subgroup results for its Long COVID drug, the first public report of these findings.

Expected impact

likely pressure as investors weigh modest benefits against overall non‑significant trial outcomes

Evidence & confidence

The data are new and materially affect expectations for the drug's path forward, but the mixed results limit upside.

Market effects

may temper enthusiasm for Long COVID therapeutics in biotech sector

limited to US biotech investors

low

Counterpoint

Investors could view the high‑inflammatory subgroup result as a catalyst for a future upside if further data confirm efficacy.

Key entities

  • BioVie Inc.

    Clinical‑stage biotech developing bezisterim for Long COVID and neurodegenerative diseases.

  • National Institute of Allergy and Infectious Diseases (NIAID)

    Co‑host of the RECOVER‑TLC workshop where data were presented.

Related articles

$BIVIHighAI 8/10

BioVie to present additional Parkinson’s drug data at international conference

BioVie Inc (BIVI, BIVIW) will present additional data on its experimental Parkinson's drug, bezisterim, at the AD/PD 2027 conference in Barcelona. The data, from the Phase 2 SUNRISE-PD trial, showed significant improvements in motor and non-motor symptoms for patients with higher inflammation. The company reported a 1.23-point improvement in treated patients versus a 1.21-point worsening in the placebo group, with a p-value of 0.0006.

$BIVIMedAI 8/10

BioVie identifies two Long COVID patient groups with distinct responses to bezisterim

BioVie Inc. (BIVI, BIVIW) reported that its Long COVID trial identified two patient groups with distinct responses to its drug bezisterim. High-inflammatory patients showed cognitive improvements, while others improved in fatigue and post-exertional malaise. The trial, involving 203 participants, did not reach statistical significance overall. BioVie plans to present more data at an upcoming conference.

$BIVIMed

BioVie 3Q 2026: EPS ($0.68) — 10-Q Summary

BioVie reported a wider quarterly loss of $5.61M, or $0.68 per share, due to increased R&D expenses and lower interest income. The company is pre-revenue. Key programs, including Parkinson's disease and Long COVID, showed positive results. The Phase 3 liver program protocol is being finalized. According to the company, R&D expenses rose primarily due to the Long COVID Phase 2 program.